Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Benefits of sport and leisure activities outweigh the risks for people with heart disease, cardiologists say

While exercise is generally beneficial for a person's overall health, physical activities may increase the risk of adverse cardiovascular disease events in certain susceptible individuals. However, cardiologists say that the benefits outweigh the risks.

19 Nov 2024

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Tirzepatide improves heart health and function in obese HFpEF patients

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

AI-powered ECG model predicts heart disease risk with precision

A new AI-enhanced ECG model, AIRE, accurately predicts mortality and heart disease risk, providing clinicians with actionable, patient-specific insights.

5 Nov 2024

Cardiac damage framework may identify patients who could benefit from earlier TAVR

Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).

29 Oct 2024

Early intervention with TAVR proves safe and effective for asymptomatic aortic stenosis

The first powered randomized trial examining early intervention with transcatheter aortic valve replacement (TAVR) in patients with asymptomatic, severe aortic stenosis (AS) found this strategy to be both a safe and effective alternative to clinical surveillance (CS).

29 Oct 2024

Research highlights importance of quality improvement programs in stroke care

New research published this month shows the key role quality improvement programs play in ensuring hospitals can adequately fight one of the biggest public health threats facing our country: stroke.

24 Oct 2024

Arthritis-style immunotherapy shows promise for heart failure

A study uncovers IL-1β signaling in cardiac fibrosis, highlighting distinct fibroblast populations and promising immunotherapy strategies for heart failure.

24 Oct 2024

NYU Langone researchers address the challenges of heart failure in cancer patients

A new scientific statement issued today by the Heart Failure Society of America highlights a critical connection between heart failure (HF) and cancer, with shared mechanisms contributing to the incidence and progression of both diseases.

16 Oct 2024

How carnitine transporters boost reproductive health

Research uncovers the critical role of carnitine transporters in maintaining fertility by regulating energy metabolism and protecting reproductive cells from oxidative stress. It suggests new pathways for treating infertility through carnitine supplementation and targeted therapies.

6 Oct 2024

NIH awards grant to study how dilated cardiomyopathy progresses to heart failure

A University of Arizona College of Medicine – Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could eventually lead to better preventive and treatment options for heart failure.

27 Sep 2024

Understanding the role of TIPS in improving renal function amid cirrhosis

Cirrhosis is one of the leading causes of mortality from non-communicable diseases, with complications arising as liver function deteriorates.

26 Sep 2024

New guidelines for cardiovascular management in noncardiac surgery released

The 2024 guideline for cardiovascular management of adults undergoing noncardiac surgery reflects a decade of updates and new evidence since the guideline's last release in 2014.

24 Sep 2024

COVID-19 mRNA vaccine linked to myocardial scarring in adolescents and young adults

The study investigates COVID-19 vaccine-related myocarditis in adolescents, revealing clinical characteristics and risks of myocardial injury in young adults.

11 Sep 2024

Aficamten improves exercise tolerance in patients with HOCM

Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac myosin inhibitors (CMIs) are being developed to help patients with hypertrophic obstructive cardiomyopathy (HOCM), a disease in which the heart muscle becomes thickened leading to reduced blood flow out of the heart.

5 Sep 2024

RESHAPE-HF2 trial shows M-TEER as effective treatment for functional mitral regurgitation

Mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalizations with improved health status in patients with HF and moderate to severe functional mitral regurgitation (FMR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

T-TEER shows promising outcomes in severe tricuspid regurgitation patients after one year

Tricuspid transcatheter edge-to-edge repair (T-TEER) significantly reduced the severity of secondary tricuspid regurgitation and improved quality of life after 1 year, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Pediatric heart transplant waitlist fails to prioritize sickest patients, study shows

The method used across the United States to wait-list children for heart transplants does not consistently rank the sickest patients first, according to a new study led by Stanford Medicine experts.

28 Aug 2024

Robotic arm-based, 5G-enabled remote echocardiograms show high diagnostic accuracy

New research presented at this year's ESC Congress 2024 in London, UK (30 Aug – 2 Sept) shows that performing echocardiograms remotely using a 5G cellular network has similar accuracy to those performed in person by cardiologists.